OPTIMAAL

OPTIMAAL

Cardiology A clinical trial–Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. See Losartan.
Mentioned in ?
References in periodicals archive ?
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart-failure after an acute myocardial infarction: results from the OPTIMAAL study.
But the most impressive finding in the OPTIMAAL analysis was that among patients who survived at least 30 days after a stroke, 33% were fully recovered with no disability at the 1month mark and another 39% had minor disability with respect to the domains of speech, vision, walking, and self-care, as rated by clinical investigators.
OPTIMAAL fingered the ACE inhibitor as first-line therapy in this setting, based upon the finding of a nonsignificant trend toward lower mortality: 16% as compared with 18% with losartan after a mean follow-up of 2.
On the other hand, losartan is a reasonable option in ACE inhibitor-intolerant patients based upon the OPTIMAAL finding that the angiotensin receptor blocker was significantly better tolerated than captopril.